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Unraveling Mysteries of the 
Multifunctional Protein SPARC
Mizuho Fukunaga-Kalabis1 and Meenhard Herlyn1
The matricellular protein SPARC (secreted protein acidic and rich in cysteine) 
has diverse functions in melanoma cells. Because this secreted protein is pro-
duced not only in tumor cells but also in stromal cells, the question has been 
asked whether paracrine effects of stroma-derived SPARC contribute to mela-
noma progression. In this issue, Prada et al. (2007) begin to answer this question 
by demonstrating that SPARC produced by melanoma, but not stromal cells, is 
essential to regulate melanoma cell growth.
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The matricellular protein osteonec-
tin/SPARC (secreted protein acidic and 
rich in cysteine) has recently attracted 
the attention of cancer researchers as 
a novel regulator of tumor cell biology. 
SPARC is highly expressed in malig-
nant melanomas. Clinically, SPARC 
expression correlates with the aggres-
siveness of melanomas and the acquisi-
tion of metastatic phenotypes (Massi et 
al., 1999). SPARC has been shown to 
have three general functions: de-adhe-
sion, antiproliferation, and regulation 
of extracellular matrix (ECM) interac-
tions (Framson and Sage, 2004). Robert 
et al. (2006) demonstrated that SPARC 
represses expression of E-cadherin 
through up-regulation of Snail, lead-
ing to migratory and invasive behavior. 
The data strongly suggest that SPARC 
functionally induces epithelial–mes-
enchymal transition and contributes to 
transformation of melanocytes to mela-
noma. It was recently revealed that 
SPARC produced by melanoma cells 
regulates inflammatory processes to 
inhibit polymorphonuclear (PMN) leu-
kocyte recruitment and antitumor cyto-
toxic capacity (Alvarez et al., 2005), 
suggesting that SPARC contributes to 
cancer immunity.
Like other matricellular proteins, such 
as osteopontin or tenascin, SPARC plays 
diverse roles in melanoma development. 
One can speculate that SPARC functions 
differently at each stage of melanoma 
progression. Moreover, several studies 
have confirmed that SPARC promotes 
tumor progression in glioma (Schultz et 
al., 2002), while it reduces tumor activi-
ties in breast cancer (Koblinski et al., 
2005). These inconsistent observations 
suggest that regulation and function of 
SPARC are dependent on cellular con-
text. Additionally, because SPARC is not 
only expressed by tumor cells but also 
secreted by surrounding fibroblasts and 
endothelial cells, it has been questioned 
whether SPARC derived from tumor 
stromal cells plays any roles in tumor 
progression. Although two groups have 
tried to dissect the functions of host-
derived SPARC using SPARC null mice, 
their results showed some discrepancy. 
Both groups observed alterations in 
tumor-associated ECM components; 
however, one group demonstrated 
enhanced tumor growth in SPARC null 
mice (Brekken et al., 2003), whereas the 
other reported reduced tumor growth 
(Sangaletti et al., 2003).
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 Growth capacity of 
human melanoma cells 
depends on SPARC 
levels produced by 
the melanoma cells 
themselves.
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In this issue, Prada et al. (2007) report 
that the in vitro and in vivo growth 
capacity of human melanoma cells 
depends on SPARC levels produced 
by melanoma cells rather than stromal 
cell-derived SPARC. Previously, the 
group demonstrated that suppression of 
SPARC expression in human melanoma 
cells using a SPARC antisense expres-
sion vector resulted in significantly 
decreased tumorigenicity (Ledda et al., 
1997). Their study used two interesting 
approaches. First, they tested in vitro 
tumor growth under both 2D and 3D 
culture (spheroid) conditions as well 
as in vivo growth in mice. Mounting 
evidence has suggested that there are 
differences in phenotype when the 
same cells are grown in 2D or 3D cul-
ture conditions (Smalley et al., 2006). 
Because a tumor mass grows in 3D, it is 
important to study the behavior of cells 
in the more physiologically relevant 
microenvironment of 3D culture rather 
than classical 2D conditions. In support 
of this, the modulation of SPARC levels 
in melanoma cells had no effect on cell 
proliferation in 2D adherent culture; 
however, suppression and hyperexpres-
sion of SPARC promoted and inhibited, 
respectively, melanoma growth in 3D 
spheroid culture. In agreement with the 
investigators’ previous results, suppres-
sion of SPARC resulted in pronounced 
inhibition of in vivo tumorigenesis. 
Whereas downregulation of SPARC 
decreased tumor growth, upregulation 
of SPARC did not impact in vivo tumor 
growth although it caused stromal reor-
ganization and increased angiogenesis.
At first look, it might seem that their 
in vitro and in vivo data are not consis-
tent. However, in vivo tumorigenicity is 
not always determined solely by prolif-
eration rate and is affected by many bio-
logical factors. In fact, the authors pro-
vide evidence that inhibition of tumor 
growth by SPARC suppression in vivo 
was likely due to melanoma rejection 
by host PMN recruitment. In a second 
interesting approach, they cocultured 
melanoma cells with human fibroblasts 
in 3D culture or coinjected them into 
nude mice to assess the role of fibro-
blast-derived SPARC. Surprisingly, 
fibroblast-derived SPARC did not affect 
the growth of heterotypic 3D spheroids 
or in vivo tumorigenesis. Why does 
SPARC not act in a paracrine manner at 
this stage of melanoma? There are a few 
clues to help unravel this mystery. It has 
been reported that SPARC functions 
are regulated by proteolytic cleavage 
(Iruela-Arispe et al., 1995; Sage et al., 
2003). Furthermore, Yan et al. (2005) 
reported that SPARC is observed both 
in the cytoplasm and in culture medi-
um; thus, SPARC functions not only as 
an extracellular protein but also poten-
tially as an intracellular protein to influ-
ence cellular activities. As discussed 
by Yan et al. (2005), the location and 
concentration of SPARC, whether it is 
intact or proteolyzed, and interactions 
between SPARC and other molecules 
also contribute to the impact of SPARC 
on target cells.
The following questions remain: 
What regulates the activation of mela-
noma-derived SPARC? Does SPARC 
act in a paracrine manner at the early 
stage of melanoma development? How 
does SPARC induce PMN infiltration? 
How do PMN cells cause tumor rejec-
tion? Elucidating these questions will 
promote the discovery of potential 
therapeutic targets for the prevention of 
melanoma progression.
CONFLICT OF INTEREST
The authors state no conflict of interest.
REFERENCES
Alvarez MJ, Prada F, Salvatierra E, Bravo AI, 
Lutzky VP, Carbone C et al. (2005) Secreted 
protein acidic and rich in cysteine produced 
by human melanoma cells modulates 
polymorphonuclear leukocyte recruitment 
and antitumor cytotoxic capacity. Cancer Res 
65:5123–32
Brekken RA, Puolakkainen P, Graves DC, 
Workman G, Lubkin SR, Sage EH (2003) 
Enhanced growth of tumors in SPARC null 
mice is associated with changes in the ECM. J 
Clin Invest 111:487–95
Framson PE, Sage EH (2004) SPARC and tumor 
growth: where the seed meets the soil? J Cell 
Biochem 92:679–90
Iruela-Arispe ML, Lane TF, Redmond D, Reilly 
M, Bolender RP, Kavanagh TJ et al. (1995) 
Expression of SPARC during development 
of the chicken chorioallantoic membrane: 
evidence for regulated proteolysis in vivo. 
Mol Biol Cell 6:327–43
Koblinski JE, Kaplan-Singer BR, VanOsdol SJ, Wu M, 
Engbring JA, Wang S, et al. (2005) Endogenous 
osteonectin/SPARC/BM-40 expression inhibits 
MDA-MB-231 breast cancer cell metastasis. 
Cancer Res 65:7370–7.
Ledda MF, Adris S, Bravo AI, Kairiyama C, Bover 
L, Chernajovsky Y et al. (1997) Suppression of 
SPARC expression by antisense RNA abrogates 
the tumorigenicity of human melanoma cells. 
Nat Med 3:171–6
Massi D, Franchi A, Borgognoni L, Reali UM, 
Santucci M (1999) Osteonectin expression 
correlates with clinical outcome in thin 
cutaneous malignant melanomas. Hum Pathol 
30:339–44
Prada F, Benedetti LG, Bravo AI, Alvarez MJ, 
Carbone C, Podhajcer OL (2007) SPARC 
endogenous level, rather than fibroblast-
produced SPARC or stroma reorganization 
induced by SPARC, is responsible for 
melanoma cell growth. J Invest Dermatol 
127:2618–28
Robert G, Gaggioli C, Bailet O, Chavey C, Abbe 
P, Aberdam E et al. (2006) SPARC represses E-
cadherin and induces mesenchymal transition 
during melanoma development. Cancer Res 
66:7516–23
Sage EH, Reed M, Funk SE, Truong T, Steadele 
M, Puolakkainen P et al. (2003) Cleavage of 
the matricellular protein SPARC by matrix 
metalloproteinase 3 produces polypeptides 
that influence angiogenesis. J Biol Chem 
278:37849–57
Sangaletti S, Stoppacciaro A, Guiducci C, Torrisi 
MR, Colombo MP (2003) Leukocyte, rather 
than tumor-produced SPARC, determines 
stroma and collagen type IV deposition in 
mammary carcinoma. J Exp Med 198:1475–
85
Schultz C, Lemke N, Ge S, Golembieski WA, 
Rempel SA (2002) Secreted protein acidic 
and rich in cysteine promotes glioma invasion 
and delays tumor growth in vivo. Cancer Res 
62:6270–7
Smalley KS, Lioni M, Herlyn M (2006) Life 
isn’t flat: taking cancer biology to the next 
dimension. In Vitro Cell Dev Biol Anim 
42:242–7
Yan Q, Weaver M, Perdue N, Sage EH (2005) 
Matricellular protein SPARC is translocated 
to the nuclei of immortalized murine lens 
epithelial cells. J Cell Physiol 203:286–94
